2. Search Result
Search Result
Results for "

XPO1-IN-1

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15970
    Verdinexor
    2 Publications Verification

    KPT-335

    		 CRM1 Apoptosis RSV Infection Inflammation/Immunology Cancer
    Verdinexor (KPT-335) is an orally active inhibitor for selective inhibitor of nuclear export (SINE). Verdinexor inhibits the respiratory syncytial virus A2 (RSV A2) replication with an IC50 of 0.96 µM. Verdinexor inhibits the function of nuclear export protein Exportin 1 (XPO1/CRM1), inhibiting pro-inflammatory responses. Verdinexor exhibits antitumor effciency .
    Verdinexor
  • HY-100423
    Eltanexor
    2 Publications Verification

    KPT-8602

    		 CRM1 Cancer
    Eltanexor (KPT-8602) is a second-generation, highly specific and orally active exportin-1 (XPO1) inhibitor with potent anti-leukemic activity. Eltanexor (KPT-8602) inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor (KPT-8602) induces Caspase-dependent apoptosis in a panel of leukemic cell lines .
    Eltanexor
  • HY-144763
    XPO1-IN-1

    		Apoptosis Cancer
    XPO1-IN-1 (compound D4) is an orally active and potent XPO1 inhibitor, with an IC50 of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research .
    XPO1-IN-1
  • HY-170672
    XPO1-ligand-1

    		CRM1 Ligands for Target Protein for PROTAC Cancer
    XPO1-ligand-1 is a target protein ligand for XPO1 and can be used to synthesize PROTAC PROTAC XPO1 degrader-1 (HY-170669) .
    XPO1-ligand-1
  • HY-170669
    PROTAC XPO1 degrader-1

    		PROTACs CRM1 Apoptosis NF-κB Cancer
    PROTAC XPO1 degrader-1 (Compound 2c) is an XPO1 degrader. PROTAC XPO1 degrader-1 exhibits anti-proliferative effects, can induce cell apoptosis, inhibit NF-κB activity, and cause cell cycle arrest in the G1 phase. PROTAC XPO1 degrader-1 can be used in research on hematological malignancies (Pink: Target Protein Ligand (HY-170672); Black: Linker (HY-W010525); Blue: E3 Ligase Ligand (HY-170671); E3 Ligase Ligand-Linker Conjugate (HY-170673)) .
    PROTAC XPO1 degrader-1
  • HY-170671
    E3 ligase Ligand 49

    		Ligands for E3 Ligase Cancer
    E3 ligase Ligand 49 serves as the E3 ubiquitin ligase ligand for PROTAC XPO1 degrader-1 (HY-170669). E3 ligase Ligand 49 can be utilized for the synthesis of PROTACs .
    E3 ligase Ligand 49
  • HY-170673
    E3 Ligase Ligand-linker Conjugate 156

    		E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 156 is a CRBN E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 156 can be used to synthesize PROTAC XPO1 degrader-1 (HY-170669) .
    E3 Ligase Ligand-linker Conjugate 156
  • HY-163902
    SP100030 analogue 1

    		CRM1 Cancer
    SP100030 analogue 1 (compound 11), a SP100030 (HY-110177) analogue, is a selective inhibitor of transcriptional activation (SITA) with an EC50 of 137 nM for suppressing the XPO1-dependent upregulation of IL2 by Jurkat-based IL2-Luc reporter assay .
    SP100030 analogue 1
  • HY-174132
    CW8001

    		CRM1 Inflammation/Immunology
    CW8001 is a covalent XPO1 (Exportin-1) inhibitor with an EC50 value of 1 nM for inhibiting T cell activation. CW8001 prevents nuclear localization of NFAT transcription factors, suppressing expression of inflammatory cytokines like IL-2. CW8001 is promising for research of T cell-driven immune diseases such as graft-versus-host disease (GVHD) .
    CW8001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: